November 2008 Pompe Program Update

Feb 4, 2009 | NEWS

Genzyme Program Update November 10th, 2008 Genzyme would like to take this opportunity to provide an update to the Pompe Community. The US Food and Drug Administration (FDA) held a meeting of its Endocrinologic and Metabolic Drugs Advisory Committee on October 21,...

IPA FAQs About the Myozyme Supply Problem

Jan 18, 2009 | NEWS

A compilation of the most pertinent information regarding the MyozymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More supply issue. The IPA has done its best to gather the most relevant and commonly asked...

AMDA Letter to Patients Regarding Supply Situation

Jan 17, 2009 | EDITORIALS

By: Tiffany House–AMDA President posted on: January 17, 2009 The AMDA is writing to our Pompe patient community to let everyone know that the AMDA has been working closely with the IPA and Genzyme in order to get communication out to our patient population about...

AMDA Statement Regarding the Management of “Myozyme” supply

Jan 17, 2009 | NEWS

The AMDA is writing to our Pompe patient community to let everyone know that the AMDA has been working closely with the IPA and Genzyme in order to get communication out to our patient population about the status of the MyozymeA form of enzyme replacement therapy used...

IPA Statement Regarding the Management of Myozyme Supply

Jan 14, 2009 | NEWS

Since the first market approval of MyozymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More, the IPA has liaised directly with Genzyme LSDA group of diseases in which substances build up inside lysosomes...

Guidance to the Pompe Community on the Management of Myozyme Supply

Jan 13, 2009 | NEWS

This guidance is being distributed to all treating physicians worldwide except those in the European Union (EU). Separate guidance will be sent to European healthcare professionals in accordance with the requirements of the European Medicines Agency (EMEA); we expect...